Obesity, Postmenopausal Women
Conditions
Brief summary
Postmenopausal women are at a risk of excessive weight gain, bone loss, hypertension, and metabolic syndrome. Obesity-induced chronic low-grade inflammation is initiated by excess nutrients in metabolic cells. Recent studies have indicated tocotrienols (one kind of vitamin E, a potent antioxidant) supplement may be good for mitigating negative impacts of obesity in postmenopausal women. The purpose of the study is to examine the effect of 24-week tocotrienols on obesity-associated outcome measurements in postmenopausal women. The investigators will enroll 60 qualified women at the start of the study and randomly assigned to no tocotrienols (placebo) or tocotrienols group for 24 weeks. Obesity-associated measurements will be recorded using blood, urine, adipose tissue, and fecal samples. All data will be analyzed statistically.
Detailed description
Postmenopausal women are at a risk of excessive weight gain, bone loss, hypertension, and metabolic syndrome. Among these risk factors, obesity is now recognized as a worldwide epidemic disease. Obesity-induced chronic low-grade inflammation is initiated by excess nutrients in metabolic cells. Aging and decline of estrogen are factors that contribute to weight gain in postmenopausal women, and approaches, such as anti-inflammatory potential in dietary antioxidants to reduce inflammation may likely combat obesity. Recent studies have indicated tocotrienols (one kind of vitamin E, a potent antioxidant) supplement may be good for mitigating negative impacts of obesity in postmenopausal women. However, no study has ever been done the role of tocotrienols in obesity-associated outcome measures in postmenopausal women. The long-term goal is to develop a new strategy featuring a dietary supplement (i.e., tocotrienols) for mitigating obesity in postmenopausal women. The purpose of the study is to examine the effect of 24-week tocotrienols on obesity-associated outcome measurements in postmenopausal women. The investigators plan to recruit postmenopausal women using flyers, non-solicited e-mail system, campus announcement, local radio, newspapers, and TV scripts. The investigators plan to enroll approximately 150-200 women to obtain 60 qualified women at the start of the study. After screening, qualified participants will be matched by body weight and age, and then randomly assigned to no tocotrienols or tocotrienols group. The outcome measures will be assessed at baseline, after 12, and after 24 weeks. Obesity-associated measurements will be recorded using blood, urine, adipose tissue, and fecal samples. The investigators will monitor safety of subjects after 12 and after 24 weeks. Food intake and physical activity will be assessed at baseline, after 12, and after 24 weeks. All data will be analyzed statistically.
Interventions
DRUGplacebo softgel
Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
Sponsors
Texas Tech University Health Sciences Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
Yes
Inclusion criteria
1. PMW with BMI ≥30 kg/m2. 2. Normal liver, kidney, and thyroid function (TSH)-sent to Quest Diagnostic Laboratory. 3. Sedentary using International Physical Activity Questionnaire (IPAQ-short form).
Exclusion criteria
1. Unstable body weight (more than 5% change in body weight) within 3 months before intervention begins. 2. Changes to medications or supplements (i.e., steroids, statins) within 3 months of the baseline study visit that could affect lipid metabolism. • If they change any medications/supplements after the baseline visit that will affect lipid metabolism, their study participation will end. 3. Taking anticoagulants that may interact with TT. 4. Serious chronic disease (e.g., unstable cardiovascular disease, uncontrolled diabetes and hypertension, and active cancer).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fat mass | 24 weeks | total and regional fat mass by DXA |
| visceral adipose tissue | 24 weeks | VAT by BIA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Oxylipins inflammation marker | 24 weeks | oxylipins levels in plasma and adipose tissue |
| Gut microbiota | 24 weeks | abundance and composition of intestinal bacteria in feces |
| hs-CRP | 24 weeks | high-sensitivity C-reactive protein in serum |
| leptin | 24 weeks | serum leptin |
| total cholesterol | 24 weeks | total cholesterol in serum |
| endocannabinoids inflammatory markers | 24 weeks | endocannabinoids levels in plasma and adipose tissue |
| HDL | 24 weeks | high density lipoprotein in serum |
| TG | 24 weeks | triglycerides in serum |
| beta-oxidation | 24 weeks | carnitine palmitoyltransferase 1A (CPT1) mRNA expression in adipose tissue |
| FASN | 24 weeks | Fatty acid synthase mRNA expression in fat tissue |
Countries
United States
Outcome results
None listed